Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
BioPharma Dive18h
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
STAT18h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
BioWorld21h
Ultromics’ AI software for cardiac amyloidosis gets FDA approval
Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...
Mashable23h
PS5 vs. PS5 Slim: What are the differences?
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. In this PS5 vs. PS5 ...